Analysis of cytokine signaling in patients with extrinsic asthma and hyperimmunoglobulin E

Background: Recent data suggest that the regulation of class switching to IgE by cytokines is mediated by STAT transcription factors. The induction of IgE by IL-4 and IL-13 occurs through the activation of the intracellular signal-transducing protein Stat6, whereas the inhibition of IgE class switching by interferon-gamma (IFN-gamma occurs through the activation of Stat1. Objective: We hypothesized that in extrinsic asthma or in cases of markedly elevated IgE tie, hyperimmunoglobulin E [HIE]) increased levels of IgE may be associated with alterations in the cytokine levels or the activation of Stat6, Methods: PBMCs and sera from 8 patients with extrinsic asthma (mean IgE, 285 +/- 100 IU/mL), 3 patients with HIE (mean IgE, 7050 +/- 1122 IU/mL), and 14 nonatopic control subjects (mean IgE, 112 +/- 28 IU/mL) were analyzed. Results: The mean IL-4 level detected by ELISA was much greater in patients with HIE than control subjects (88.6 +/- 11.5 pg/mL vs 11.5 +/- 7.1 pg/mL, P =.005), and increased IL-4 levels among patients with both asthma and HIE correlated with the increased IgE levels, In contrast, IL-13 levels were not elevated. Levels of Stat6 protein present in PBMCs did not differ in the patients and control subjects. Examination of Stat6 DNA-binding activity demonstrated no activation of IL-4 signaling in patients with either HIE or acute asthma, Interestingly, evidence for the presence of B cells that have already switched to IgE was seen in PBMCs of several patients with asthma or HIE. Conclusion: These results indicate that (1) IgE production in asthma and HIE usually is associated with elevated levels of IL-4, but not IL-13, in the peripheral blood; (2) the increased sera IL-4 levels in asthma and HIE are not sufficient to induce Stat6 activation in PBMCs; and (3) evidence of switch recombination to E may be detected in isolated cases of elevated IgE, This implies that high levels of IgE in these patients either results from B cells that have already undergone class switching, from Ig class switching that is localized to target tissues, or both.